Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):257–262. doi: 10.1038/bjc.1998.474

Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]

A Yokoyama 1, Y Kurita 1, N Saijo 1, T Tamura 1, K Noda 1, K Shimokata 1, T Matsuda 1
PMCID: PMC2062904  PMID: 9683303

Abstract

Irinotecan hydrochloride (CPT-11) shows marked anti-tumour activity alone and in combination with cisplatin in non-small-cell lung cancer (NSCLC). It is necessary to investigate combined-modality therapy including novel effective anti-cancer agents to improve long-term survival of patients with unresectable stage III NSCLC. A phase I/II study of concurrent chemoradiotherapy with CPT-11 and cisplatin was conducted to determine the maximum tolerated dose (MTD) and efficacy in this group of patients. Thirteen previously untreated patients with unresectable stage IIIA/B NSCLC were enrolled and efficacy and toxicity was evaluated in 12 of them; one patient was ineligible. Chemotherapy was repeated every 4 weeks for three courses. Radiation therapy was started on day 2 of the first course of chemotherapy and 60 Gy in 30 fractions was given over 6 weeks. Four of six patients enrolled at level 1 completed the scheduled treatment. Another two received only one and two courses of chemotherapy as a result of persistent leucopenia and neutropenic fever respectively. Three of six patients given level 2 therapy completed the scheduled treatment. Another three received only one and two courses of chemotherapy, two refused treatment because of diarrhoea and one died of pneumonia. Radiation therapy was inadequate in these three patients. As the CPT-11 dose intensity in this trial was low, because of the necessity of omitting CPT-11 administration on days 8 and/or 15 as a result of leucopenia or diarrhoea, and the low radiation therapy completion rate, the trial was discontinued at level 2. Five patients at level 1 and three at level 2 showed partial responses, an overall response rate of 67%. Although neither MTD nor dose-limiting toxicity could be identified, chemotherapy with CPT-11 and cisplatin plus concurrent radiation therapy was deemed unacceptable. We are now conducting a phase I/II study of chemotherapy using CPT-11 as a single agent in combination with radiation therapy.

Full text

PDF
257

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boothman D. A., Trask D. K., Pardee A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 1989 Feb 1;49(3):605–612. [PubMed] [Google Scholar]
  2. Dillman R. O., Herndon J., Seagren S. L., Eaton W. L., Jr, Green M. R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996 Sep 4;88(17):1210–1215. doi: 10.1093/jnci/88.17.1210. [DOI] [PubMed] [Google Scholar]
  3. Dillman R. O., Seagren S. L., Propert K. J., Guerra J., Eaton W. L., Perry M. C., Carey R. W., Frei E. F., 3rd, Green M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940–945. doi: 10.1056/NEJM199010043231403. [DOI] [PubMed] [Google Scholar]
  4. Falk S. J., Smith P. J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol. 1992 Jun;61(6):749–757. doi: 10.1080/09553009214551601. [DOI] [PubMed] [Google Scholar]
  5. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16–20. doi: 10.1200/JCO.1992.10.1.16. [DOI] [PubMed] [Google Scholar]
  6. Greco F. A., Stroup S. L., Gray J. R., Hainsworth J. D. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1996 May;14(5):1642–1648. doi: 10.1200/JCO.1996.14.5.1642. [DOI] [PubMed] [Google Scholar]
  7. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996 Apr;14(4):1065–1070. doi: 10.1200/JCO.1996.14.4.1065. [DOI] [PubMed] [Google Scholar]
  8. Kim J. H., Kim S. H., Kolozsvary A., Khil M. S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys. 1992;22(3):515–518. doi: 10.1016/0360-3016(92)90865-f. [DOI] [PubMed] [Google Scholar]
  9. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M., Lacombe-Terrier M. J., Douillard J. Y., Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991 Mar 20;83(6):417–423. doi: 10.1093/jnci/83.6.417. [DOI] [PubMed] [Google Scholar]
  10. Masuda N., Fukuoka M., Takada M., Kusunoki Y., Negoro S., Matsui K., Kudoh S., Takifuji N., Nakagawa K., Kishimoto S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol. 1992 Nov;10(11):1775–1780. doi: 10.1200/JCO.1992.10.11.1775. [DOI] [PubMed] [Google Scholar]
  11. Negoro S., Fukuoka M., Masuda N., Takada M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Niitani H., Taguchi T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991 Aug 21;83(16):1164–1168. doi: 10.1093/jnci/83.16.1164. [DOI] [PubMed] [Google Scholar]
  12. Pei X. H., Nakanishi Y., Takayama K., Bai F., Kawasaki M., Tsuruta N., Mizuno K., Hara N. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs. 1997 Mar;8(3):231–237. doi: 10.1097/00001813-199703000-00003. [DOI] [PubMed] [Google Scholar]
  13. Perez C. A., Pajak T. F., Rubin P., Simpson J. R., Mohiuddin M., Brady L. W., Perez-Tamayo R., Rotman M. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987 Jun 1;59(11):1874–1881. doi: 10.1002/1097-0142(19870601)59:11<1874::aid-cncr2820591106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  14. Sause W. T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., Emami B., Curran W. J., Byhardt R. W., Turrisi A. T. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995 Feb 1;87(3):198–205. doi: 10.1093/jnci/87.3.198. [DOI] [PubMed] [Google Scholar]
  15. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., Kirkpatrick A., Koolen M., Maat B., Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20;326(8):524–530. doi: 10.1056/NEJM199202203260805. [DOI] [PubMed] [Google Scholar]
  16. Tamura K., Takada M., Kawase I., Tada T., Kudoh S., Okishio K., Fukuoka M., Yamaoka N., Fujiwara Y., Yamakido M. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res. 1997 Feb;88(2):218–223. doi: 10.1111/j.1349-7006.1997.tb00369.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tobinai K., Kohno A., Shimada Y., Watanabe T., Tamura T., Takeyama K., Narabayashi M., Fukutomi T., Kondo H., Shimoyama M. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993 Aug;23(4):250–257. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES